Abstract
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Current Cancer Therapy Reviews
Title: Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Volume: 4 Issue: 4
Author(s): Paul J. Cozzi, John Kearsley and Yong Li
Affiliation:
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Abstract: Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Export Options
About this article
Cite this article as:
Cozzi J. Paul, Kearsley John and Li Yong, Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413371
DOI https://dx.doi.org/10.2174/157339408786413371 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology On the Comparison of Classifiers for Microarray Data
Current Bioinformatics Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Recent Progress in Synthesis and Applications of Fluorinated Carbohydrates
Current Organic Chemistry Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Increasing Testosterone Levels and Effects on Cognitive Functions in Elderly Men and Women: A Review
Current Drug Targets - CNS & Neurological Disorders Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Urinary Biomarkers for Prostate Cancer
Current Drug Metabolism Application of Hyperthermia for Cancer Treatment: Recent Patents Review
Recent Patents on Anti-Cancer Drug Discovery Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Impaired Expression and Function of Signaling Pathway Enzymes by Anthocyanins: Role on Cancer Prevention and Progression
Current Enzyme Inhibition Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases
MicroRNA